Ricerc@Sapienza

Objectives: To investigate the incidence of bleeding events in atrial fibrillation (AF) patients treated with vitamin K (VKAs) or non-vitamin K antagonist oral anticoagulants (NOACs) screened for the presence of liver fibrosis (LF). Background: Previous studies provided conflicting results on bleeding risk in AF patients with liver disease on VKAs, and no data on NOACs in this setting are available. Methods: Post-hoc analysis of a prospective, observational multicentre study including 2330 AF outpatients treated with VKAs (n = 1297) or NOACs (n = 1033).

Background: Alpha-1 antitrypsin deficiency (AATD) is an important, inherited cause of chronic liver disease. Marked variation in fibrosis stages in patients with homozygous deficiency and those factors that determine whether heterozygous carriers develop liver fibrosis, remain unexplained. Murine studies implicate polymerized alpha-1 antitrypsin (AAT) within hepatocytes as pathogenic.

Nonalcoholic steatohepatitis (NASH) is the critical stage of nonalcoholic fatty liver disease
(NAFLD). The persistence of necroinflammatory lesions and fibrogenesis in NASH is the leading cause
of liver cirrhosis and, ultimately, hepatocellular carcinoma. To date, the histological examination of
liver biopsies, albeit invasive, remains the means to distinguish NASH from simple steatosis (NAFL).
Therefore, a noninvasive diagnosis by serum biomarkers is eagerly needed. Here, by a proteomic